# US 10,946,066 B2 · Methods for organ regeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,066 B2
- Document ID: US10946066B2
- Status: Granted
- Kind: B2
- Application number: 13/884,484
- Filed: 2011-11-09
- Published: 2013-08-29
- Granted: 2021-03-16
- Earliest claimed: 2010-11-09
- Assignees: Cornell University
- Applicants: Shahin Rafii; Bi-Sen Ding; Sina Y. Rabbany
- Inventors: Shahin Rafii; Bi-Sen Ding; Sina Y. Rabbany
- Web page: https://patentgrep.com/patent/US10946066B2

## CPC

- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/067: {Hepatocytes}
- C12N 2502/28: Vascular endothelial cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of enhancing or initiating regeneration of an organ in a subject in need thereof comprising the administration of endothelial cells specific to said organ, or inductive endothelial cells specific to said organ, into the area of the body in which organ regeneration is desired in said subject.

## Claims

### Claim 1

A method of enhancing or initiating lung regeneration , comprising administering a substantially purified population of matrix metalloproteinase-14 positive (MMP14+) inductive pulmonary endothelial cells to a subject in need of lung regeneration, wherein
the subject has a defect in or deficiency of non-endothelial cells within the lung, and
wherein following the administration, the proliferation or function of non-endothelial cells within the lung is enhanced or improved.

### Claim 2 (depends on 1)

The method of claim 1, wherein said administering is intravenous or intratracheal transplantation.

### Claim 3 (depends on 2)

The method of claim 2, further comprising administration of one or more of MMP14, vascular endothelial growth factor-A (VEGF-A), or fibroblast growth factor (FGF).

### Claim 4 (depends on 2)

The method of claim 2, further comprising administration of epithelial progenitor cells.

### Claim 5 (depends on 2)

The method of claim 2, wherein said endothelial cells are vascular endothelial growth factor receptor 2 positive (VEGFR2+), VE-cadherin+, CD34+, CD31+, and fibroblast growth factor receptor 1-positive (FGFR1+).

### Claim 6 (depends on 2)

The method of claim 2, further comprising obtaining the endothelial cells by selection of MMP14+ cells, prior to administration of said substantially purified cells to said subject.

### Claim 7 (depends on 6)

The method of claim 6, further comprising culturing the endothelial cells prior to administration of said cells.

### Claim 8 (depends on 1, 2, 3, 5, 6, 7)

The method of any one of claim 1, 2-3 or 5-7 wherein the endothelial cells have been transfected or transduced with E4 open reading frame 1 (E4ORF1).